Business Context and Reporting Period
This Form 8-K was filed by Catalyst Biosciences, Inc. (not Gyre Therapeutics, Inc.) on May 9, 2022. The filing serves as a current report to announce the company's financial results for the quarter ended March 31, 2022. The registrant is incorporated in Delaware and trades on the Nasdaq under the symbol CBIO.
Key Financial Metrics
The provided filing text acts as a cover document referencing a press release (Exhibit 99.1) for detailed data. Consequently, the filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity. Investors must refer to the attached press release for specific financial figures.
Material Changes
The filing text does not contain specific data regarding material changes versus the prior comparable period. It solely confirms the issuance of a press release containing the Q1 2022 results.
Guidance, Outlook, and Risks
The filing includes a standard disclaimer stating that the information furnished in Item 2.02 and Exhibit 99.1 is not deemed "filed" under Section 18 of the Exchange Act and is not subject to the liabilities of that section. No specific guidance, outlook, management commentary, or risk factors are detailed within the text of this 8-K form itself.
Investor Verification Checklist
- Verify the specific revenue and net loss figures in the attached Exhibit 99.1 (Press Release).
- Confirm the company's cash position and burn rate as of March 31, 2022, from the press release.
- Review the press release for any updates on clinical trial progress or regulatory milestones.
- Note that the filing text explicitly disclaims liability for the furnished information under Section 18 of the Exchange Act.